• 1
    Kaplan JE, Hanson D, Dworkin MS et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30: S5S14.
  • 2
    Deeks SG, Hecht FM, Swanson M et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13: F35F43.
  • 3
    Forrest DM, Seminari E, Hogg RS et al. The incidence and spectrum of AIDS-defining ilnesses in persons treated with antiretroviral drugs. Clin Infect Dis 1998; 27: 13791385.
  • 4
    Paul S, Gilbert HM, Ziecheck W, Jacobs J, Sepkowitz KA. The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS 1999; 13: 415418.
  • 5
    Ives NJ, Gazzard BG, Easterbrook PJ. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. J Infect 2001; 42: 134139.
  • 6
    Shelburne SA, Hamill RJ, Rodriguez-Barradas MC et al. Immune reconstitution inflammatory syndrome. Emergence of a unique syndrome during highly active antiretroviral therapy. Medicine 2002; 81: 213227.
  • 7
    Jones JL, Hanson DL, Dworkin MS, Ward JW, Jaffe HW. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. J Acquir Immune Defic Syndr 1999; 21: S11S17.
  • 8
    Torres RA, Baney M, Barr MR. Stabilization of in-patient daily census despite continued reduction in HIV-related admission at a New York City hospital. Program and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February, 1998 [Abstract 203].
  • 9
    Detels R, Tarwater P, Phair JP et al. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001; 16: 347355.
  • 10
    Dore GJ, Li Y, McDonald A, Ree H, Kaldo JM. Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia. J Acquir Immune Defic Syndr 2002; 29: 388395.
  • 11
    Lederberger B, Egger M, Erard V et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy. The Swiss HIV Cohort Study. J Am Med Assoc 1999; 282: 22202226.
  • 12
    Perez-Olmeda M, Machuca A, Garcia-Samaniego J, Soriano V. HAART does not modify HCV replication in HIV-HCV coinfected patients. Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, January–February 1999 [Abstract 193].
  • 13
    Tor J, Tural C, Ojanguren I et al. Histological damage of hepatitis C in HIV-infected patients. Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January–February 1999 [Abstract 192].
  • 14
    Wolff AJ, O'Donnell AE. Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy. Chest 2001; 120: 18881893.
  • 15
    De Gaetano Donati K, Bertagnolio S, Tumbarello M et al. Effect of highly active antiretroviral therapy on the incidence of bacterial pneumonia in HIV-infected subjects. Int J Antimicrob Agents 2000; 16: 357360.
  • 16
    Jones JL, Hanson DL, Dworkin MS, DeCock KM. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The adult/adolescent spectrum of HIV disease group. Int J Tuberc Lung Dis 2000; 4: 10261031.
  • 17
    Bower M, Powles T, Nelson M et al. HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 2003; 14: 371375.
  • 18
    Brodt HR, Kamps BS, Gute P et al. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997; 11: 17311738.
  • 19
    Michaels J and the Adult Spectrum of Disease Cohort. Opportunistic incidence rates from the Tulane/adult spectrum of disease cohort, 1994–98. Program and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA, Chicago, IL, February 1998 [Abstract 325].
  • 20
    Janssen RS. Epidemiology and neuroepidemiology of human immunodeficiency virus infection, In: BergerJR, LevyRM, eds. AIDS and the Nervous System, 2nd edn. Philadelphia, Lippincott-Raven 1997: 1337.
  • 21
    Neuenburg JK, Brodt HR, Herndier BG et al. HIV-related neuropathology, 1985–99: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31: 171177.
  • 22
    Abgrall S, Rabaud C, Costagliola D. Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy. Clin Infect Dis 2001; 33: 17471755.
  • 23
    Maschke M, Kastrup O, Esser S, Ross B, Hengge U, Hufnagel A. Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy. J Neurol Neurosurg Psychiatry 2000; 69: 376380.
  • 24
    Masliah E, DeTeresa RM, Mallory ME et al. Changes in pathologic findings at autopsy in AIDS cases for the last 15 years. AIDS 2000; 14: 6974.
  • 25
    Gendelman HE, Zheng J, Coulter CL et al. Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. J Infect Dis 1998; 178: 10001007.
  • 26
    Markus R, Brew BJ. HIV-1 peripheral neuropathy and combination antiretroviral therapy. Lancet 1998; 352: 19061907.
  • 27
    Ammassari A, Cingolani A, Pezzotti P et al. AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. Neurology 2000; 55: 11941200.
  • 28
    Hoffmann C, Tabrizian S, Wolf E et al. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 2001; 15: 21192127.
  • 29
    Cinque P, Pierotti C, Vigano MG et al. The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J Neurovirol 2001; 7: 358363.
  • 30
    Safdar A, Rubocki RJ, Horvath JA, Narayan KK, Waldron RL. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. Clin Infect Dis 2002; 35: 12501257.
  • 31
    Sewell D. Schizophrenia and HIV. Schizophren Bull 1996; 22: 465473.
  • 32
    Torre D, Fraticelli C, Gualandi E, Gambarini S, Tambini R. Impact of HAART on acute psychosis patients with AIDS. XIV International AIDS Conference. Barcelona, July 2002, 327–330.
  • 33
    De Castro S, Migliau G, Silvestri A. Heart involvement in AIDS: a prospective study during various stages of the disease. Eur Heart J 1992; 13: 14521459.
  • 34
    Corallo S, Mutinelli MR, Moroni M et al. Echocardiography detects myocardial damage in AIDS: prospective study in 102 patients. Eur Heart J 1998; 9: 887892.
  • 35
    Hsia J, Ross AM. Pericardial effusion and pericardiocentesis in human immunodeficiency virus infection. Am J Cardiol 1994; 74: 9496.
  • 36
    Acierno LJ. Cardiac complications in acquired immunodeficiency syndrome (AIDS): a review. J Am Coll Cardiol 1989; 17: 11441154.
  • 37
    Pugliese A, Isnardi D, Saini A, Scarabelli T, Raddino R, Torre D. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 2000; 40: 282284.
  • 38
    Passalaris JD, Sepkowitz KA, Glesby MJ. Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis 2000; 31: 787797.
  • 39
    Klein D, Hurley LB, Quesenberry CP, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30: 471477.
  • 40
    Rickerts V, Brodt H, Staszewski S et al. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort. Eur J Med Res 2000; 5: 329333.
  • 41
    Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702710.
  • 42
    Holmberg SD, Moorman AC, Williamson JM et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360: 17471748.
  • 43
    Friiss-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 11791193.
  • 44
    Winston J, Klotman PE. Are we missing an epidemic of HIV-associated nephropathy? J Am Soc Nephrol 1996; 7: 17.
  • 45
    US Renal Data System (USRDS). USRDS 1998 Annual Data Report. Bethesda, MD, National Institute of Diabetes and Digestive and Kidney Diseases, National Health Institutes 1998.
  • 46
    Connolly JO, Weston Ce Hendry BM. HIV-associated renal disease in London hospitals. Q J Med 1995; 88: 627634.
  • 47
    Mattana J, Siegal FP, Schwartzwald E et al. AIDS-associated membranous nephropathy with advanced renal failure: response to prednisone. Am J Kidney Dis 1997; 30: 116119.
  • 48
    Nochy D, Glotz D, Dosquet P et al. Renal disease associated with HIV infection: a multicentric study of 60 patients from Paris hospitals. Nephrol Dial Transplant 1993; 8: 1119.
  • 49
    Michel C, Dosquet P, Ronco P, Mongenot B, Viron B, Mignon E. Nephropathy associated with human immunodeficiency virus: a report of 11 cases including 6 treated with zidovudine. Nephron 1992; 62: 434440.
  • 50
    Wali RK, Drachenberg CI, Papadimitriou JC, Keay S, Ramos E. HIV-1-associated nephropathy and response to highly-active antiretroviral therapy. Lancet 1998; 352: 783784.
  • 51
    Dellow E, Unwin R, Miller R, Williams I, Griffiths M. Protease inhibitor therapy for HIV infection: the effect of HIV-associated nephrotic syndrome. Nephrol Dial Transplant 1999; 14: 744747.
  • 52
    Szczech LA. Renal diseases associated with human immunodeficiency virus infection: epidemiology, clinical course, and management. Clin Infect Dis 2001; 33: 115119.
  • 53
    Bruggeman LA, Dikman S, Meng C, Quaggin SE, Coffman TM, Klotman PE. Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J Clin Invest 1997; 100: 8492.
  • 54
    Perinbasekar S, Brod-Miller C, Pal S, Mattana J. Predictors of survival in HIV-infected patients on hemodialysis. Am J Nephrol 1996; 16: 280286.
  • 55
    Schwartz EJ, Szczech L, Winston AJ, Klotman PE. Effect of HAART on HIV-associated nephropathy (abstract A0882). J Am Soc Nephrol 2000; 11: 165a.
  • 56
    Olyaei AJ, De Mattos AM, Bennett WM. Renal toxicity of protease inhibitors. Cur Opin Nephrol Hypertens 2000; 9: 473476.
  • 57
    Karras A, Lafaurie M, Furco A et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36: 10701073.
  • 58
    Lane GP, Lucas CR, Smalwood RA. The gastrointestinal and hepatic manifestations of the acquired immune deficiency syndrome. Med J Aust 1989; 150: 139143.
  • 59
    Monkemuller KE, Wilcox CM. Diagnosis and treatment of colonic disease in AIDS. Gastrointest Endosc Clin North Am 1998; 8: 889891.
  • 60
    Monkemuller KE, Call SA, Lazenby AJ, Wilcox CM. Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral therapy. Am J Gastroenterol 2000; 95: 457462.
  • 61
    Pollok RC. Viruses causing diarrhoea in AIDS. Novartis Found Symp 2001; 238: 276283.
  • 62
    Nelson MR, Shanson DC, Hawkins DA et al. Salmonella, Campylobacter and Shigella in HIV-seropositive patients. AIDS 1992; 6: 1495.
  • 63
    Carr A, Marriott D, Field A, Vasak E, Cooper DA. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998; 351: 256261.
  • 64
    Miao YM, Awad-El-Kariem FM, Franzen C et al. Eradication of cryptosporidia and microsporida following successful antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 25: 124129.
  • 65
    O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the intial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003; 34: 407414.
  • 66
    Anastasi JK, Capili B. HIV and diarrhea in the era of HAART: 1998 New York State hospitalizations. Am J Infect Control 2000; 28: 262266.
  • 67
    Poles MA, Dieterich DT, Schwarz ED et al. Liver biopsy findings in 501 patients with HIV. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11: 170177.
  • 68
    Bodsworth N, Donovan B, Nightgale B. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989; 160: 577582.
  • 69
    Eyster ME, Diamondstone LS, Lien JM, Ehman WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused haemophiliacs: effect of coinfection with human immunodeficiency virus. J Acquir Immune Defic Syndr 1993; 6: 602610.
  • 70
    Den Brinker M, Wit FW, Wertheim-van Dillen PM et al. Hepatitis B and C virus coinfection and the risk for hepatoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14: 28952902.
  • 71
    Manegold C, Hannoun C, Wywiol A et al. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2001; 32: 144148.
  • 72
    Soto B, Sanchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 15.
  • 73
    Zylberberg H, Chaix ML, Rabian C et al. Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects. Clin Infect Dis 1998; 26: 11041106.
  • 74
    Gavazzi G, Richallet G, Morand P et al. Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV. Pathol Biol 1998; 46: 1215.
  • 75
    Torre D, Tambini R, Cadario F, Barbarini G, Moroni M, Basilico C. Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients with highly active antiretroviral therapy. Clin Infect Dis 2001; 33: 15791585.
  • 76
    Rutschmann OT, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin LH. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998; 177: 783785.
  • 77
    Ragni MV, Bontempo FA. Increase in hepatitis C virus load in haemophiliacs during treatment with highly active antiretroviral therapy. J Infect Dis 1999; 180: 20272029.
  • 78
    Babik JM, Holodniy M. Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients. J Virol 2003; 77: 19401950.
  • 79
    Fialaire P, Payan C, Vitour D et al. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection. J Infect Dis 1999; 180: 574575.
  • 80
    Yokozaki S, Takamatsu J, Nakano I et al. Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy. Blood 2000; 96: 42934299.
  • 81
    Ramirez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, Anaya-Saavedra G, Gonzalez-Ramirez I, Ponce de Leon S. The changing clinical spectrum of human immunodeficiency virus (HIV)-related oral lesions in 1,000 consecutive patients: a 12-year study in a referral center in Mexico. Medicine 2003; 82: 3950.
  • 82
    Ceballos-Salobrena A, Gaitan-Cepeda LA, Ceballos-garcia L, Lezama-del Valle D. Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS? AIDS Patient Care STDS 2000; 14: 627635.
  • 83
    Smith C, Lilly S, Mann KP et al. AIDS-related malignancies. Ann Med 1998; 30: 323344.
  • 84
    International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92: 18231830.
  • 85
    Ledergerber B, Telenti A, Egger M. Risk of HIV-related Kaposi's sarcoma and non-Hodgkin lymphoma with potent antiretroviral therapy: prospective cohort study. Br Med J 1999; 319: 2324.
  • 86
    Levine AM, Tulpule A. Clinical aspects and management of AIDS-related Kaposi's sarcoma. Eur J Cancer 2001; 37: 12881295.
  • 87
    Sgadari C, Barillari G, Toschi E et al. HIV protease inhbitors are potent anti-angiogenic molecules and promote regression of Kaposi's sarcoma. Nat Med 2002; 8: 225232.
  • 88
    Patton LL, McKaig R, Strauss R et al. Changing prevalence of oral manifestations of human immunodeficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 89: 299304.
  • 89
    Greenspan D, Canchola AJ, MacPhail LA, Cheikh B, Greenspan JS. Effect of highly antiretroviral therapy on frequency of oral warts. Lancet 2001; 357: 14111412.
  • 90
    King MD, Reznik DA, O'Daniels CM, Larsen NM, Osterholt D, Blumberg HM. Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 2002; 34: 641648.
  • 91
    Tappero JW, Perkins BA, Wenger JD, Berger TG. Cutaneous manifestations of opportunistic infections in patients with human immunodeficiency virus. Clin Microbiol Rev 1995; 8: 440450.
  • 92
    Kreuter A, Schugt I, Hartmann M, Rasokat H, Altmeyer P, Brockmeyer NH. Dermatological diseases and signs of HIV infection. Eur J Med Res 2002; 7: 5762.
  • 93
    Calista D, Morri M, Stagno A, Boschini A. Changing morbidity of cutaneous diseases in patients with HIV after the introduction of highly active antiretroviral therapy including a protease inhibitor. Am J Clin Dermatol 2002; 3: 5962.
  • 94
    Pepose JS, Holland GN, Nestor MS et al. Acquired immune deficiency syndrome: pathogenic mechanisms of ocular disease. Ophthalmology 1985; 92: 472484.
  • 95
    Morinelli EN, Dugel PU, Lee M et al. Opportunistic intraocular infections in AIDS. Trans Am Ophthalmol Soc 1992; 90: 97108.
  • 96
    Jalali S, Reed JB, Mizoguchi M, Flynn N, Gordon J, Morse LS. Effect of highly active antiretroviral therapy on the incidence of HIV-related cytomegalovirus retinits and retinal detachment. AIDS Patient Care STDS 2000; 14: 343346.
  • 97
    Lin DY, Warren JF, Lazzeroni LC, Wolitz RA, Mansour SE. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy in HIV infected patients: natural history and clinical predictors. Retina 2002; 22: 268277.
  • 98
    Deayton JR, Wilson P, Sabin CA et al. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS 2000; 14: 11631170.
  • 99
    Chang Y, Cesarman E, Pessin MS et al. Identification of herpsevirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 18651869.
  • 100
    Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Defic Syndr 2003; 32: 527533.
  • 101
    Ratner L, Lee J, Tang S et al. Chemotherapy for HIV associated non-Hodgkin lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001; 19: 21712178.
  • 102
    Glaser S, Clarke CA, Gulley ML et al. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the greater San Francisco bay area, 1988–98. Cancer 2003; 98: 300309.
  • 103
    Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine MD. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS 1998; 12: 14591464.
  • 104
    Lillo FB, Ferrari D, Veglia F et al. HPV infection and associated cervical disease in HIV infected women: effect on highly active antiretroviral therapy. J Infect Dis 2001; 184: 547551.
  • 105
    De Gaetano Donati K, Tumbarello M, Tacconelli E et al. Impact of highly active antiretroviral therapy (HAART) on the incidence of bacterial infections in HIV-1 infected subjects. J Chemother 2003; 15: 6065.
  • 106
    Chang L, Ernst T, Witt MD et al. Persistent brain abnormalities in antiretroviral-naïve HIV patients 3 months after HAART. Antivir Ther 2003; 8: 1726.
  • 107
    McCormack JG, Bowler SD, Donnelly JE, Steadman C. Miliary tuberculosis with paradoxical expansion of intracranial tuberculomas complicating immunodeficiency virus infection in a patient receiving highly active antiretroviral therapy. Clin Infect Dis 1998; 26: 10081009.
  • 108
    Postelmans L, Payen MC, De Wit S, Caspers-Velu L. Neovascularization of the optic disc after highly active antiretroviral therapy in an AIDS patient with cytomegalovirus retinitis. A new immune recovery-related ocular disorder? Ocular Immunol Inflamm 1999; 7: 237240.